- Home
- MGNX vs BYSI Comparison
MGNX vs BYSI Comparison
Compare MGNX & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- BYSI
- Stock Information
- Founded
- MGNX 2000
- BYSI 2010
- Country
- MGNX United States
- BYSI United States
- Employees
- MGNX N/A
- BYSI N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- MGNX Health Care
- BYSI Health Care
- Exchange
- MGNX Nasdaq
- BYSI Nasdaq
- Market Cap
- MGNX 99.7M
- BYSI 80.6M
- IPO Year
- MGNX 2013
- BYSI 2017
- Fundamental
- Price
- MGNX $1.76
- BYSI $1.80
- Analyst Decision
- MGNX Hold
- BYSI
- Analyst Count
- MGNX 5
- BYSI 0
- Target Price
- MGNX $3.25
- BYSI N/A
- AVG Volume (30 Days)
- MGNX 582.9K
- BYSI 27.9K
- Earning Date
- MGNX 08-14-2025
- BYSI 08-13-2025
- Dividend Yield
- MGNX N/A
- BYSI N/A
- EPS Growth
- MGNX N/A
- BYSI N/A
- EPS
- MGNX N/A
- BYSI N/A
- Revenue
- MGNX $165,495,000.00
- BYSI N/A
- Revenue This Year
- MGNX N/A
- BYSI N/A
- Revenue Next Year
- MGNX N/A
- BYSI N/A
- P/E Ratio
- MGNX N/A
- BYSI N/A
- Revenue Growth
- MGNX 303.47
- BYSI N/A
- 52 Week Low
- MGNX $0.99
- BYSI $0.98
- 52 Week High
- MGNX $5.10
- BYSI $3.44
- Technical
- Relative Strength Index (RSI)
- MGNX 57.55
- BYSI 36.99
- Support Level
- MGNX $1.69
- BYSI $1.96
- Resistance Level
- MGNX $1.87
- BYSI $1.84
- Average True Range (ATR)
- MGNX 0.12
- BYSI 0.11
- MACD
- MGNX 0.02
- BYSI -0.00
- Stochastic Oscillator
- MGNX 71.59
- BYSI 7.14
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.